{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:08:03Z","timestamp":1778576883338,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.antiviral.2019.104637","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T11:17:54Z","timestamp":1572002274000},"page":"104637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection"],"prefix":"10.1016","volume":"172","author":[{"given":"Marcus Wing Choy","family":"Loe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina Ching Hua","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin Jang Hann","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104637_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/bdra.20102","article-title":"Angiotensin II receptor antagonist treatment during pregnancy","author":"Alwan","year":"2005","journal-title":"Birth Defects Res. Part A Clin. Mol. Teratol."},{"issue":"8","key":"10.1016\/j.antiviral.2019.104637_bib2","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/brain\/aww158","article-title":"Zika virus-associated neurological disorders: a review","volume":"139","author":"Araujo","year":"2016","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.antiviral.2019.104637_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A screen of FDA-approved drugs for inhibitors of zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.104637_bib4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104637_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx009","article-title":"Pediatric drug nitazoxanide: a potential choice for control of Zika","volume":"4","author":"Cao","year":"2017","journal-title":"Open Forum Infect. Dis."},{"issue":"10","key":"10.1016\/j.antiviral.2019.104637_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2006-7-10-r100","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104637_bib7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0035-9203(52)90042-4","article-title":"Zika Virus (I). Isolations and serological specificity","volume":"46","author":"Dick","year":"1952","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2019.104637_bib8","article-title":"RNA virus mutations and fitness for survival","author":"Domingo","year":"2002","journal-title":"Annu. Rev. of Microbiol."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104637_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002636","article-title":"Molecular evolution of Zika virus during its emergence in the 20(th) century","volume":"8","author":"Faye","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2019.104637_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02483-10","article-title":"Appraising the roles of CBLL1 and the ubiquitin\/proteasome system for flavivirus entry and replication","author":"Fernandez-Garcia","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104637_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s00234-016-1687-9","article-title":"Magnetic resonance imaging findings in Guillain-Barr\u00e9 syndrome caused by Zika virus infection","author":"Fontes","year":"2016","journal-title":"Neuroradiology"},{"key":"10.1016\/j.antiviral.2019.104637_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2008.11.034","article-title":"West Nile virus genome amplification requires the functional activities of the proteasome","author":"Gilfoy","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.104637_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(08)60238-X","article-title":"Pathogenic flaviviruses","author":"Gould","year":"2008","journal-title":"The Lancet"},{"key":"10.1016\/j.antiviral.2019.104637_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2016.03.009","article-title":"Zika virus: epidemiology, clinical features and host-virus interactions","author":"Hamel","year":"2016","journal-title":"Microb. Infect."},{"key":"10.1016\/j.antiviral.2019.104637_bib15","doi-asserted-by":"crossref","DOI":"10.3201\/eid1509.090442","article-title":"Zika virus outside Africa","author":"Hayes","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104637_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.08.007","article-title":"Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice","volume":"146","author":"Kamiyama","year":"2017","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104637_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1128\/AAC.01467-12","article-title":"Inhibition of Chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression","volume":"57","author":"Kaur","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104637_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2016.12.022","article-title":"Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism","volume":"139","author":"Kuivanen","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104637_bib19","doi-asserted-by":"crossref","DOI":"10.1046\/j.1523-1755.2003.00192.x","article-title":"Angiotensin II regulates 11\u03b2-hydroxysteroid dehydrogenase type 2 via AT2 receptors","author":"Lanz","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.antiviral.2019.104637_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.04.003","article-title":"Antiviral activity of pinocembrin against Zika virus replication","volume":"167","author":"Lee","year":"2019","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104637_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2008.01.004","article-title":"Molecular strategies to inhibit the replication of RNA viruses","volume":"78","author":"Leyssen","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104637_bib22","article-title":"AXL-mediated productive infection of human endothelial cells by zika virus","author":"Liu","year":"2016","journal-title":"Circ. Res."},{"issue":"01","key":"10.1016\/j.antiviral.2019.104637_bib23","doi-asserted-by":"crossref","first-page":"062","DOI":"10.4172\/jaa.1000009","article-title":"Antiviral activity of emetine dihydrochloride against dengue virus infection","volume":"01","author":"Low","year":"2009","journal-title":"J. Antivir. Antiretrovir."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104637_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00003495-199856050-00013","article-title":"Candesartan cilexetil. A review of its use in essential hypertension","volume":"56","author":"McClellan","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2019.104637_bib25","series-title":"Straus SE. Fields Virology. Fields Virology","article-title":"Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses","author":"Melnick","year":"1996"},{"issue":"3","key":"10.1016\/j.antiviral.2019.104637_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/CMR.00072-15","article-title":"Zika virus","volume":"29","author":"Musso","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"issue":"10","key":"10.1016\/j.antiviral.2019.104637_bib27","doi-asserted-by":"crossref","first-page":"O595","DOI":"10.1111\/1469-0691.12707","article-title":"Rapid spread of emerging Zika virus in the Pacific area","volume":"20","author":"Musso","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2019.104637_bib28","series-title":"Angiotensin II Induction of Fibronectin Biosynthesis in Cultured Human Mesangial Cells: Association with CREB Transcription Factor","author":"Nahman","year":"1996"},{"issue":"5","key":"10.1016\/j.antiviral.2019.104637_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/imj.13059","article-title":"Zika virus: an emerging infectious threat","volume":"46","author":"Ong","year":"2016","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.antiviral.2019.104637_bib30","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.12688\/f1000research.9648.1","article-title":"Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library","volume":"5","author":"Pascalino","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.antiviral.2019.104637_bib31","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1602113","article-title":"Zika virus","author":"Petersen","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9386","key":"10.1016\/j.antiviral.2019.104637_bib32","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2019.104637_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00561-10","article-title":"Characterization of dengue virus resistance to brequinar in cell culture","author":"Qing","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104637_bib34","series-title":"Proceedings of the National Academy of Sciences","article-title":"AXL-dependent infection of human fetal endothelial cells distinguishes Zika virus from other pathogenic flaviviruses","author":"Richard","year":"2017"},{"key":"10.1016\/j.antiviral.2019.104637_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2018.01.002","article-title":"Current concerns and perspectives on Zika virus co-infection with arboviruses and HIV","author":"Rothan","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.antiviral.2019.104637_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00411-17","article-title":"The race to find antivirals for zika virus","volume":"61","author":"Saiz","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104637_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2017.03.001","article-title":"Zika virus: history, epidemiology, transmission, and clinical presentation","volume":"308","author":"Song","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.antiviral.2019.104637_bib38","doi-asserted-by":"crossref","DOI":"10.1007\/s11262-009-0411-9","article-title":"Genetic characterization of 2006-2008 isolates of Chikungunya virus from Kerala, South India, by whole genome sequence analysis","author":"Sreekumar","year":"2010","journal-title":"Virus Genes"},{"key":"10.1016\/j.antiviral.2019.104637_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-04138-1","article-title":"Viperin is an important host restriction factor in control of Zika virus infection","volume":"7","author":"Van Der Hoek","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.104637_bib40","first-page":"2","article-title":"WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations","volume":"37","author":"WHO | World Health Organization","year":"2016","journal-title":"WHO"},{"key":"10.1016\/j.antiviral.2019.104637_bib41","author":"World Health Organization"},{"issue":"10","key":"10.1016\/j.antiviral.2019.104637_bib42","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nm.4184","article-title":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen","volume":"22","author":"Xu","year":"2016","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104637_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421930347X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421930347X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:29:43Z","timestamp":1759062583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421930347X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":43,"alternative-id":["S016635421930347X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104637","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104637"}}